Skip to main content

Table 4 Multivariate Survival Analysis - All-Cause Mortality, by Stage

From: Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)

  

Stage I-II

Stage III-IV

  

HR

p-value

95% CI

HR

p-value

95% CI

Age

         
 

66-< 70

ref

   

ref

   
 

70-< 75

1.40

< 0.001

1.16

1.70

1.32

< 0.01

1.12

1.55

 

75-< 80

1.72

< 0.0001

1.43

2.07

1.74

< 0.0001

1.48

2.04

 

≥ 80

2.90

< 0.0001

2.44

3.45

2.45

< 0.0001

2.11

2.85

Gender

         
 

Female

ref.

       
 

Male

1.12

0.02

1.02

1.23

1.06

0.17

0.97

1.16

Race

         
 

White

ref.

       
 

Black

1.16

0.24

0.91

1.49

1.35

0.01

1.08

1.69

 

Other

0.99

0.93

0.83

1.19

1.20

0.04

1.01

1.42

DLBCL histology

         
 

9680

ref.

       
 

9684

1.45

0.02

1.07

1.96

1.39

0.02

1.06

1.83

Stage at diagnosis

         
 

I

ref.

   

N/A

   
 

II

1.29

< 0.0001

1.17

1.41

N/A

   
 

III

N/A

   

ref.

   
 

IV

N/A

   

1.38

< 0.001

1.16

1.66

NCI Comorbidity Index

         
 

0

ref.

       
 

1

1.23

< 0.001

1.10

1.38

1.13

0.03

1.01

1.26

 

2

1.47

< 0.0001

1.25

1.73

1.38

< 0.0001

1.18

1.61

 

≥3

1.99

< 0.0001

1.65

2.39

1.73

< 0.0001

1.44

2.08

Year of diagnosis

         
 

2001

ref.

       
 

2002

0.94

0.40

0.82

1.08

0.80

< 0.01

0.70

0.91

 

2003

0.86

0.04

0.75

1.00

0.78

< 0.001

0.68

0.89

 

2004

0.88

0.10

0.76

1.02

0.77

< 0.001

0.67

0.88

 

2005

0.88

0.09

0.75

1.02

0.75

< 0.0001

0.65

0.86

Percent of 25+ year olds in census tract with some college

         
 

0-< 25%

ref.

       
 

25-< 50%

1.04

0.47

0.93

1.16

0.97

0.56

0.87

1.08

 

≥50%

0.54

0.09

0.26

1.09

1.28

0.45

0.68

2.42

Percent living in poverty in census tract

         
 

0-< 5%

ref.

       
 

5-< 7%

1.06

0.43

0.92

1.23

1.02

0.78

0.88

1.18

 

7-< 12%

1.00

1.00

0.87

1.14

1.09

0.18

0.96

1.24

 

≥12%

1.21

< 0.01

1.06

1.39

1.12

0.09

0.98

1.27

SEER region

         
 

CA

ref.

       
 

CT

1.16

0.15

0.95

1.42

1.04

0.75

0.84

1.28

 

Detroit

1.10

0.35

0.90

1.33

1.19

0.07

0.99

1.43

 

HI

0.71

0.13

0.46

1.11

0.87

0.53

0.57

1.34

 

IA

0.91

0.38

0.75

1.12

1.01

0.95

0.84

1.21

 

NM

1.09

0.61

0.79

1.49

1.27

0.13

0.93

1.73

 

Seattle

0.98

0.87

0.78

1.23

1.03

0.75

0.85

1.25

 

UT

1.04

0.75

0.81

1.34

1.01

0.94

0.78

1.31

 

Atlanta

1.28

0.12

0.94

1.74

0.82

0.19

0.62

1.10

 

Rural GA

0.93

0.86

0.41

2.10

1.09

0.87

0.40

2.96

 

KY

1.01

0.91

0.84

1.21

1.27

0.01

1.06

1.51

 

LA

1.05

0.65

0.86

1.27

1.06

0.54

0.88

1.29

 

NJ

1.26

< 0.01

1.08

1.47

1.04

0.60

0.90

1.21

Lymph node site

         
 

Nodal

ref.

       
 

Extranodal

1.13

0.01

1.03

1.24

0.94

0.52

0.77

1.14

Other conditions

         
 

Anemia

1.37

< 0.0001

1.18

1.60

1.25

< 0.01

1.08

1.44

 

Neutropenia

1.53

0.35

0.62

3.77

0.59

0.37

0.19

1.87

 

Thrombocytopenia

1.23

0.49

0.69

2.19

0.96

0.87

0.61

1.53

 

Cardiovascular disease

1.33

< 0.001

1.14

1.54

1.18

0.04

1.01

1.37

  1. HR: Hazard Ratio
  2. N/A: Not Applicable
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us